Article
Polygenic Liability for Antipsychotic Dosage and Polypharmacy - A Real-World Registry and Biobank Study
2023-09-25
Abstract excerpt
<title>Abstract</title> <p>Genomic prediction of antipsychotic dose and polypharmacy has been difficult, mainly due to limited access to large cohorts with genetic and drug prescription data. In this proof of principle study, we investigated if genetic liability for schizophrenia is associated with high dose requirements of antipsychotics and antipsychotic polypharmacy, using real-world registry and biobank data...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 14cd210a-d8ca-56bd-abf9-7f1d2082a1f6
- DOI
- 10.21203/rs.3.rs-3308026/v1
